Five Versus Three Years of Adjuvant Imatinib in Patients at Significant Risk for Recurrence Following Complete Resection of Primary Gastrointestinal Stromal Tumor: A Phase III, Randomized, Multicenter Study (FAITH study)
Latest Information Update: 21 Mar 2018
At a glance
- Drugs Imatinib (Primary)
- Indications Gastrointestinal stromal tumours
- Focus Therapeutic Use
- Acronyms FAITH study
Most Recent Events
- 21 Mar 2018 New trial record